nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

March 22, 2018

(Length of Discussion: 16 min)

Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS).  It is exciting that early treatment in the M0 CRPC patients is leading to favorable outcomes.

Fred Saad, MD. FRCS, is Professor and Chief of Urology and Director of GU Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is Director of the molecular oncology research lab in Prostate Cancer. He is the past Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. Dr. Saad has been involved in most of the important clinical trials in advanced prostate cancer over the last 20 years and presently sits on 7 steering committees of international clinical trials. In 2014 he received the lifetime achievement award for research from the CHUM Research Center.

Alicia Morgans, MD, MPH. 

Read the full video transcript

email news signup